As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
US PRIVATE equity firm Bain Capital said it may withdraw its tender offer proposal for Japanese IT firm Fuji Soft, after ...
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.
Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback